IQAir Introduces New XE Smart Air Purifiers

IQAir, a Swiss air quality technology company, launches their new XE air purifiers, the next generation of their best-selling high-performance air purifiers, in North America.

IQAir XE air purifiers feature a redesigned fan system that is up to three times more energy efficient than previous models. With Wi-Fi smart app integration, the air purifiers can be remotely controlled and fully integrated with IQAir’s AirVisual air quality app and platform. The XEs also include three smart modes, allowing for sensor-based operation and prompting automatic adjustment of the air purifier performance based on measured air quality.

Designed and made in Switzerland, the XE line also includes an advanced particle sensor that measures harmful fine particulate pollutants (PM2.5), for real-time insight of indoor air. PM2.5 includes a wide range of pollutants, including smoke, dust, pollen, mold spores, house dust mites, and pet allergens. The HealthPro XE utilizes IQAir’s patented HyperHEPA filtration, which captures over 99.5% of harmful ultrafine pollution particles and biological contaminants down to 0.003 microns in size. This includes particulate matter equal in size of bacteria and viruses such as those that cause COVID-19, the flu, and even the common cold.

Frank Hammes, Global CEO, IQAir.

“The XE line pairs the newest air quality monitoring technology with our award-winning, ultra efficient filtration. Built-in air quality sensors allow the system to automatically adjust filtration according to indoor air quality. This saves energy, extends filter life, and fully automates the removal of even the smallest particles from the air.”

For the North American market, the enhanced features of the XE air purifiers are incorporated into four of IQAir’s popular air purifiers and are now available on iqair.com/us/:

  • HealthPro Plus XE is priced at $1,199
  • HealthPro Compact XE is priced at $1,099
  • GC MultiGas XE is priced at $1,599
  • GCX MultiGas XE is priced at $2,499
SourceIQAir

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”